Valimumab/Infinifer policy in 2025

Durvalumab/Infinifer (Durvalumab), as an immune checkpoint inhibitor, has shown great potential in the field of cancer treatment. At present, durvalumab has been approved for marketing in the Chinese market and is mainly used to treat various cancers such as small cell lung cancer and non-small cell lung cancer (NSCLC). By targeting PD-L1, it relieves the inhibitory effect of the immune system and enhances the body's immune cells' recognition and killing of cancer cells. However, despite being on the market, durvalumab has not yet been included in the domestic medical insurance system, which is still a considerable financial burden for many patients.

In China, the common specifications of durvalumab are 120mg/2.4mL and 500mg/10mL. The price of each box usually ranges from more than 4,000 yuan to more than 10,000 yuan. The high price of the drug may limit its use for some patients because it is not yet covered by medical insurance. This price difference is closely related to factors such as the production cost of the drug, import taxes, and exchange rate fluctuations. The common specifications of the generic drug durvalumab in overseas markets are 120mg/2.4mL, and each box sells for about more than one thousand US dollars. Affected by exchange rate fluctuations, the price may also fluctuate.

At present, the generic drug of durvalumab has not yet been launched, which means that in the domestic market, patients can only choose the original drug, which is relatively expensive. Although durvalumab has been reimbursed by medical insurance in some other countries, in China, due to various factors, it has not yet been included in the medical insurance list, making it difficult for some patients to afford its treatment costs.

With the widespread application of durvalumab in the field of cancer treatment, especially its remarkable efficacy in malignant tumors such as lung cancer and bladder cancer, it is likely to usher in policy changes in the Chinese market in the future. This move will undoubtedly improve the accessibility of the drug and benefit more cancer patients.

Reference materials: https://www.imfinzi.com/